Voyager Therapeutics, Inc., a biotech firm headquartered in Cambridge, Massachusetts, is making waves in the field of gene therapy and neurology disease treatment. The company's standout candidate is VY-TAU01, an anti-tau antibody program aiming to combat Alzheimer's disease. Voyager is also developing VY-FXN01 for Friedreich's ataxia and a superoxide dismutase 1 gene silencing program for amyotrophic lateral sclerosis. In addition, the biotech firm is working on a GBA1 gene replacement program to address Parkinson's disease and a research program for Huntington's disease treatment. Voyager has notable collaboration and license agreements with Pfizer Inc., Neurocrine Biosciences, Inc., and Novartis Pharma, A.G. to research, develop, and commercialize adeno-associated virus gene therapy products. The company was established in 2013 and has since become a prominent name in the biotech industry.
Voyager Therapeutics Inc's ticker is VYGR
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Voyager Therapeutics Inc
It is voyagertherapeutics.com
Voyager Therapeutics Inc is in the Healthcare sector
Voyager Therapeutics Inc is in the Biotechnology industry
The following five companies are Voyager Therapeutics Inc's industry peers: